Company news

Protalix BioTherapeutics, Inc. news in 2026

Protalix BioTherapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Protalix BioTherapeutics to Announce Third Quarter 2026 Financial Results and Business Update on November 10, 2026

November 3, 2026

Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results

August 12, 2026

Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026

August 5, 2026

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

May 13, 2026

Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026

May 6, 2026

Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results

March 18, 2026

Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026

March 11, 2026

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) ▼

March 9, 2026

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU

January 30, 2026

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU

January 30, 2026

Protalix BioTherapeutics Letter to Stockholders

January 5, 2026

Calls in 2026

Decks in 2026